Form 4: Christobel Selecky Acquires Stock Options in ImmunityBio, Inc.

Director Christobel Selecky reports acquisition of stock options in ImmunityBio, Inc. on June 11, 2024.

Summary

• Christobel Selecky, a director of ImmunityBio, Inc., filed a Form 4 to report changes in beneficial ownership.
• The transaction occurred on June 11, 2024.
• Selecky acquired 77,633 stock options with an exercise price of $5.96.
• These options vest on the earlier of June 11, 2025, or the date immediately preceding the next annual meeting of stockholders, contingent upon continued service as a Service Provider.
• The options expire on June 11, 2034.
• Following the transaction, Selecky directly owns 77,633 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document is a standard regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information about the transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the stock options is contingent upon the reporting person's continued service, suggesting an incentive for continued involvement with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment, as it can be interpreted as a sign of confidence in the company's future prospects.

Key Dates